# Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia

> **NCT00923013** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 175 (actual)

## Conditions studied

- Hairy Cell Leukemia

## Interventions

- **DRUG:** Cladribine
- **DRUG:** Rituximab
- **PROCEDURE:** BMbx
- **DIAGNOSTIC_TEST:** MRI
- **DIAGNOSTIC_TEST:** EKG
- **DIAGNOSTIC_TEST:** Echocardiogram
- **DIAGNOSTIC_TEST:** Abdominal/splenic ultrasound
- **PROCEDURE:** Stress test

## Key facts

- **NCT ID:** NCT00923013
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2008-10-20
- **Primary completion:** 2024-07-15
- **Final completion:** 2030-01-31
- **Target enrollment:** 175 (ACTUAL)
- **Last updated:** 2025-08-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00923013

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00923013, "Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00923013. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*